02 January 2025
: Case report
[In Press] Rare Presentation of Middle Ear Neuroendocrine Tumor: A Case Report
Unknown etiology, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Patient complains / malpractice, Unexpected drug reaction, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Nan Zeng1ABCD, Qiong Yang1ABCD, Jing Hu1ABG, Shang Yan2EFDOI: 10.12659/AJCR.945602
Am J Case Rep In Press; DOI: 10.12659/AJCR.945602
Available online: 2025-01-02, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Neuroendocrine tumors (NETs) of the middle ear are exceptionally rare, representing less than 2% of primary ear tumors in adults. These neoplasms originate from neuroendocrine cells within the middle ear cavity, posing significant diagnostic and therapeutic challenges.
CASE REPORT
We present a 27-year-old man with a 2-month history of left-sided hearing loss, tinnitus, and ear fullness. Comprehensive assessments, including tuning fork tests, pure tone audiometry, computed tomography (CT) scan of the temporal bone, and magnetic resonance imaging (MRI), were conducted. Differential diagnoses, included cholesteatoma and other middle ear masses, but chronic suppurative otitis media was not considered due to the intact tympanic membrane. Intraoperative findings revealed a pale pink mass encasing the ossicular chain, confirmed as a neuroendocrine tumor (CK [+], Syn [+++], CK18 [+], EMA [++], CD56 [-], CgA [+], Ki67 [2%+]) by immunohistochemistry. The tumor was excised via an endoscopic tympanotomy. Postoperative follow-up over 2 years showed no recurrence or metastasis, and the patient reported no significant hearing impairment affecting quality of life.
CONCLUSIONS
Middle ear neuroendocrine tumors require meticulous diagnostic workup and precise surgical intervention. This case adds to the limited body of evidence supporting that middle ear neuroendocrine tumors, although rare, can be managed effectively with tailored surgical approaches. Continued case reporting will be vital to enhance understanding and to refine treatment guidelines for optimal patient outcomes.
Keywords: Case Reports; Neuroendocrine Tumors; Ear, Middle
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946074
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946165
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946414
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944665
Most Viewed Current Articles
21 Jun 2024 : Case report
89,141
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,239
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,805
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,697
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030